This work was supported by a grant from Key Science-Technology Project of Hubei Province China (No 2007AA301B43).
Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase1
Article first published online: 3 JUN 2008
© 2008 CPS and SIMM
Acta Pharmacologica Sinica
Volume 29, Issue 6, pages 698–706, June 2008
How to Cite
SHANG, J., CHEN, L.-l., XIAO, F.-x., SUN, H., DING, H.-c. and XIAO, H. (2008), Resveratrol improves non-alcoholic fatty liver disease by activating AMP-activated protein kinase. Acta Pharmacologica Sinica, 29: 698–706. doi: 10.1111/j.1745-7254.2008.00807.x
- Issue published online: 3 JUN 2008
- Article first published online: 3 JUN 2008
- Received 2008-02-17 Accepted 2008-04-02
- insulin resistance;
- AMP-activated protein kinase;
- non-alcoholic fatty liver disease
Aim: To investigate whether resveratrol (RSV) can improve non-alcoholic fatty liver disease (NAFLD) and to find the possible mechanism. Methods: Rats fed a high-fat diet were treated with RSV. The liver histology was observed. Hyperinsulinemic euglycemic clamp was performed to assess insulin sensitivity. Fat accumulation was induced in HepG2 cells, and the cells were treated with RSV. AMP-activated protein kinase (AMPK) phosphorylation levels were determined both in the animal study and cell study. Results: Rats fed a high-fat diet developed abdominal obesity, NAFLD, and insulin resistance (IR), which were markedly improved by 10 weeks of RSV administration. RSV treatment prevented triacylglycerol (TG) accumulation in HepG2 cells that were incubated with high concentration of glucose and insulin. Both in vivo and in vitro studies showed that RSV treatment could promote the phosphorylation of AMPK, which in this study, suppressed 2 lipogenesis gene expressions, contributing to the improvement of NAFLD and IR. Conclusion: The results indicated that by reducing TG accumulation and improving IR, RSV could protect the liver from NAFLD. The activation of AMPK was involved in the mechanism. RSV has the therapeutic potential for preventing or treating NAFLD and IR-related metabolic disorders.